scholarly journals Remdesivir in Pregnant Patients with Novel Coronavirus Disease 2019: Case Series

2021 ◽  
Author(s):  
Renu Singh ◽  
Anjoo Agrawal ◽  
Mona Asnani
Keyword(s):  
Case Series ◽  
Novel Coronavirus

scholarly journals Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)

2021 ◽  
Author(s):  
Biyan Nathanael Harapan ◽  
Hyeon Joo Yoo
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Case Reports ◽  
Case Series ◽  
Altered Mental Status ◽  
Neurological Complications ◽  
Neurological Symptoms ◽  
Neurological Manifestations ◽  
Fisher Syndrome ◽  
Novel Coronavirus ◽  
The Impact

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is responsible for the outbreak of coronavirus disease 19 (COVID-19) and was first identified in Wuhan, China in December 2019. It is evident that the COVID-19 pandemic has become a challenging world issue. Although most COVID-19 patients primarily develop respiratory symptoms, an increasing number of neurological symptoms and manifestations associated with COVID-19 have been observed. In this narrative review, we elaborate on proposed neurotropic mechanisms and various neurological symptoms, manifestations, and complications of COVID-19 reported in the present literature. For this purpose, a review of all current published literature (studies, case reports, case series, reviews, editorials, and other articles) was conducted and neurological sequelae of COVID-19 were summarized. Essential and common neurological symptoms including gustatory and olfactory dysfunctions, myalgia, headache, altered mental status, confusion, delirium, and dizziness are presented separately in sections. Moreover, neurological manifestations and complications that are of great concern such as stroke, cerebral (sinus) venous thrombosis, seizures, meningoencephalitis, Guillain–Barré syndrome, Miller Fisher syndrome, acute myelitis, and posterior reversible encephalopathy syndrome (PRES) are also addressed systematically. Future studies that examine the impact of neurological symptoms and manifestations on the course of the disease are needed to further clarify and assess the link between neurological complications and the clinical outcome of patients with COVID-19. To limit long-term consequences, it is crucial that healthcare professionals can early detect possible neurological symptoms and are well versed in the increasingly common neurological manifestations and complications of COVID-19.

A Case Series of SARS-CoV-2 RT-PCR-Positive Hospitalized Infants 60 Days of Age or Younger From 2 New York City Pediatric Emergency Departments

2021 ◽  
Vol 60 (4-5) ◽  
pp. 247-251
Author(s):  
Ameer Hassoun ◽  
Nessy Dahan ◽  
Christopher Kelly
Keyword(s):  
New York ◽  
Case Reports ◽  
Severe Disease ◽  
Case Series ◽  
Pediatric Emergency ◽  
Rt Pcr ◽  
Vulnerable Group ◽  
Mild Disease ◽  
Young Infants ◽  
Novel Coronavirus

The emergence of novel coronavirus disease-2019 poses an unprecedented challenge to pediatricians. While the majority of children experience mild disease, initial case reports on young infants are conflicting. We present a case series of 8 hospitalized infants 60 days of age or younger with coronavirus disease-2019. A quarter of these patients had coinfections (viral or bacterial). None of these infants had severe disease. Continued vigilance in testing this vulnerable group of infants is warranted.

scholarly journals Management challenges in patients with comorbid COVID-19 associated delirium and serious mental illness – A case series

2021 ◽  
pp. 009121742098597
Author(s):  
Saba Syed ◽  
Michael Couse ◽  
Rashi Ojha
Keyword(s):  
Mental Illness ◽  
Serious Mental Illness ◽  
Healthcare Providers ◽  
Case Series ◽  
Retrospective Chart Review ◽  
Active Management ◽  
The Novel ◽  
Psychiatric Facility ◽  
Medical Teams ◽  
Novel Coronavirus

Background There is still a lot unknown about the novel Coronavirus Disease 19 (COVID-19) and its effects in humans. This pandemic has posed several challenging clinical situations to healthcare providers. Objective We hope to highlight the distinctive challenges that COVID-19 presents in patients with serious mental illness and what steps primary medical teams can take to co-manage these patients with the psychiatry consultants. Methods We present a retrospective chart review of four patients who were on psychotropic polypharmacy and admitted to our hospital from the same long-term psychiatric facility with COVID-19 delirium and other associated medical complications. Results We illustrate how the primary medical teams and psychiatrists collaborated in clinical diagnosis, treatment, and management. Conclusions Patients with serious mental illness and COVID-19 infection require active collaboration between primary medical teams and psychiatrists for diagnostic clarification, reduction of psychotropic polypharmacy to avoid adverse effects and drug-drug interactions, prevention of psychiatric decompensation, and active management of agitation while balancing staff and patient safety concerns.

scholarly journals Citations and publication rate of preprints on pharmacological interventions for COVID-19: The good, the bad and, the ugly.

2020 ◽  
Author(s):  
Bryan Nicolalde ◽  
Diego Añazco ◽  
Mariam Mushtaq ◽  
Isabel Espinosa ◽  
Jimena Gimenez ◽  
...  
Keyword(s):  
Case Series ◽  
Science Research ◽  
Publication Rate ◽  
Pharmacological Interventions ◽  
Result Section ◽  
Scholarly Journals ◽  
Novel Coronavirus ◽  
Reported Data ◽  
Study Type ◽  
Number Of Citations

Abstract Background: Preprints are preliminary reports that have not been peer-reviewed. On December 2019, a novel coronavirus appeared in China, and since then, scientific production, including preprints, has drastically increased. In this study, we intend to evaluate how often preprints regarding pharmacological interventions against COVID-19 were cited, in spite of the fact that some of these preprints remained unpublished.Methods: We conducted a search on medRxiv and bioRxiv to identify preprints related to pharmacological interventions against SARS-CoV-2 from January 1, 2020 to March 31, 2020. We included any study type that addressed or reported data on pharmacological interventions. We gathered metadata on June 26, 2020 of included preprints and identified if they had been published in a scholarly journal. We performed Mann-Whitney U tests to evaluate if published articles had differences in citation counts or metrics, as defined by PDF downloads and abstract reads, when compared to unpublished preprints.Results: Our sample included 97 preprints, of which 23 were published on scholarly journals and 74 remained unpublished (Publication rate of 23,7%). The most common study designs we found among preprints were basic science research and case series. The number of citations in our sample ranged from 0 to 1409 for published articles, and ranged from 0 to 175 citations for unpublished preprints. Published articles had a significantly higher number of citations when compared to unpublished preprints (p=0,000013). We did not find a statistical difference in PDF download (p=0,167) and abstract reads (p= 0,181). In the published articles, the time from posting on a preprint server to publication on a journal ranged from 0 to 98 days (median: 42.0 days). The time period from date of submission to a journal to date of acceptance in our sample ranged from 1 to 228 days (median: 23 days). Almost half of the preprints that were subsequently published (47,8%) had modifications made to the result section after peer-review.Conclusions: The publication rate of the preprints in this sample was low (1 in 4), although review times in scholarly journals seems to be accelerated. However, there was no difference in the number of views or downloads between preprints already published in scholarly journals and those not yet.

scholarly journals Venovenous ECMO treatment, outcomes, and complications in adults according to large case series: A systematic review

2020 ◽  
pp. 039139882097540
Author(s):  
Jun Hyun Kim ◽  
Marina Pieri ◽  
Giovanni Landoni ◽  
Anna Mara Scandroglio ◽  
Maria Grazia Calabrò ◽  
...  
Keyword(s):  
Systematic Review ◽  
Treatment Outcomes ◽  
Influenza A ◽  
Influenza Pandemic ◽  
Case Series ◽  
H1n1 Influenza ◽  
Novel Coronavirus ◽  
Ecmo Treatment ◽  
Vv Ecmo ◽  
Large Case

Background: Venovenous extracorporeal membrane oxygenation (VV ECMO) has gained popularity for the treatment of refractory respiratory failure during and after the 2009 influenza pandemic, and still represents a precious therapeutic resource for severe novel coronavirus 2019 infection. However, most of the published studies are small case series, and only two randomized trials exist in literature. Aim: Aim of this systematic review is to describe trends in VV ECMO treatment outcomes according to large studies only. Methods: We searched and included studies with more than 100 VV ECMO cases dated up to August 1st, 2019. Results: Thirty-three studies published in the period 2011–2019 met inclusion criteria, for a total of 12,860 patients (age 46.3 ± 17.4 years). ARDS was mainly by pneumonia, in 3126 (37%) cases; further 401(7%) patients had H1N1 Influenza A infection. Cannulation-related complications occurred in 502 (7%) cases. Weighted mean (95% confidence interval) of VV ECMO duration was 8.9 (8.7–9.1) days, and ICU stay was 23.6 (22.4–24.8) days. Mortality at the longest follow up available was 40%. Data collection in 70% of the studies had a duration of >5 years. Conclusion: This study reveals the characteristics of large case VV ECMO studies.

scholarly journals Emergence of the first manic episode in recovered COVID-19 patients: A case series from Egypt

2021 ◽  
Author(s):  
Hayam M. Elgohary ◽  
Mohammad G. Sehlo ◽  
Usama M. Youssef ◽  
Mohamed Abdelghani
Keyword(s):  
Neuropsychiatric Symptoms ◽  
Gastrointestinal Symptoms ◽  
Case Series ◽  
Manic Episode ◽  
Behavioral Changes ◽  
Future Research ◽  
The Novel ◽  
Manic Symptoms ◽  
Global Pandemic ◽  
Novel Coronavirus

Abstract Objective In December 2019, the novel coronavirus (COVID-19) infection was first reported in Wuhan city, China, which had rapidly spread as a global pandemic. This infection was commonly presented by respiratory and /or gastrointestinal symptoms. However, it is still unclear whether COVID-19 infection could be associated with central nervous system (CNS) damage which would result in development of neuropsychiatric symptoms. Method A total of five cases of suddenly emerged manic episodes during the pandemic of COVID-19 were extensively described. We presented the symptoms and described the diagnosis, clinical course, and treatment of each case. Results All patients had positive findings of ribonucleic acid (RNA) tests for COVID-19 in specimens of their sputum. The patients later developed manic symptoms during and after the recovering period of their illness. Conclusions The case series of newly emerged manic symptoms associated with COVID-19 infection highlights the essential need for evaluation of mental health status and would contribute to our understanding of the potential risk of CNS affection by COVID-19 infection. The limited number of cases would limit the generalizability of association. Future research should investigate the behavioral changes accompanying and following COVID-19 infection.

scholarly journals Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China.

2020 ◽  
Author(s):  
Dawei Wang ◽  
Yimei Yin ◽  
Chang Hu ◽  
Xing Liu ◽  
Xingguo Zhang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Kidney Injury ◽  
Clinical Course ◽  
Case Series ◽  
Kidney Injury ◽  
Retrospective Case ◽  
Illness Onset ◽  
Independent Risk Factors ◽  
Systemic Symptoms ◽  
Novel Coronavirus

Abstract Background In December 2019, Coronavirus Disease 2019 (COVID-19) outbreak was reported from Wuhan, China. Information on the clinical course and prognosis of COVID-19 was not thoroughly described. We described the clinical courses and prognosis in COVID-19 patients. Methods Retrospective case series of COVID-19 patients from Zhongnan Hospital of Wuhan University in Wuhan, and Xi-shui Hospital, Hubei Province, China, up to February 10, 2020. Epidemiological, demographic and clinical data were collected. Clinical course of survivors and non-survivors were compared. Risk factors for death were analyzed. Results A total of 107 discharged patients with COVID-19 were enrolled. The clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 after illness onset was characterized by fever, cough, dyspnea, lymphopenia and radiological multilobar pulmonary infiltrates. In severe cases, thrombocytopenia, acute kidney injury, acute myocardial injury or adult respiratory distress syndrome were observed. During week 2, in mild cases, fever, cough and systemic symptoms began to resolve and platelet count rose to normal range, but lymphopenia persisted. In severe cases, leukocytosis, neutrophilia and deteriorating multi-organ dysfunction were dominant. By week 3, mild cases had clinically resolved except for lymphopenia. However, severe cases showed persistent lymphopenia, severe acute respiratory dyspnea syndrome , refractory shock, anuric acute kidney injury, coagulopathy, thrombocytopenia and death. Older age and male sex were independent risk factors for poor outcome of the illness. Conclusions A period of 7–13 days after illness onset is the critical stage in COVID-19 course. Age and male gender were independent risk factors for death of COVID-19.

scholarly journals Respiratory Viral Co-infection with Novel Coronavirus in Children: A Case Series

2020 ◽  
Author(s):  
Emily Hertzberg ◽  
C. Anthoney Lim ◽  
Erick Eiting ◽  
Steven Yung ◽  
Jeranil Nunez ◽  
...  
Keyword(s):  
Clinical Presentation ◽  
Case Series ◽  
Respiratory Viruses ◽  
World Health ◽  
Clinical Implications ◽  
The Novel ◽  
Global Pandemic ◽  
Surgical Evaluation ◽  
Novel Coronavirus ◽  
Health Organization

Abstract Background:The novel coronavirus, COVID-19 was identified in January 2020 initially in Wuhan, China but quickly spread worldwide and was declared a global pandemic by the World Health Organization on March 11, 2020. There are more than 185 countries impacted and the numbers of cases and deaths continues to rise. The rate of coinfections with COVID-19 in children and the clinical implications are unknown.Case Presentation:We describe the clinical presentation and course of three patients with COVID-19 and coinfections with other common respiratory viruses. Two cases were diagnosed with COVID-19 as well as rhinovirus/enterovirus and the third case was COVID-19 and pertussis. Each case had a unique presentations and hospital courses including an emergency room discharge, urgent surgical evaluation and an intensive care unit admission.Conclusions:This is the first US-based case report to discuss coinfections with COVID-19 and other respiratory viruses. Decisions regarding diagnosis and management of children in the setting of the current pandemic should account for the possibility of coinfections. We also highlight publish health challenged resulting from children with the novel coronavirus.

Sign in / Sign up

Export Citation Format

Share Document